Skip Navigation

Cardiovascular Research 2006 70(3):543-554; doi:10.1016/j.cardiores.2006.02.018
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Kehat, I.
Right arrow Articles by Aronheim, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kehat, I.
Right arrow Articles by Aronheim, A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2006, European Society of Cardiology

Inhibition of basic leucine zipper transcription is a major mediator of atrial dilatation

Izhak Kehata,b, Ronit Heinrichb, Ofer Ben-Izhakc, Hiroshi Miyazakid, J. Silvio Gutkinde and Ami Aronheimb,*

aDepartment of Internal Medicine C and Cardiology, Rambam Medical Center, Haifa, Israel
bDepartment of Molecular Genetics, The B. Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, 7 Efron St., Bat-Galim, Haifa 31096, Israel
cDepartment of Pathology, Rambam Medical Center, Israel
dPhilips Institute of Oral and Craniofacial Molecular Biology, Richmond, VA, USA
eOral and Pharyngeal Cancer Branch, National Institute of Dental Research, National Institute of Health, Bethesda, MD, USA

* Corresponding author. Tel.: +972 4 8295226; fax: +972 4 8295225. Email address: aronheim{at}tx.technion.ac.il

Objective Atrial fibrillation is the most prevalent clinically significant cardiac arrhythmia. Atrial dilatation, a predictor of atrial fibrillation, is thought to result from increased ventricular pressure. However, the underlying molecular mechanisms responsible for atrial dilatation are largely unknown. Here we sought to examine whether the expression of a basic leucine zipper inhibitor protein, JDP2, in the heart is sufficient for the generation of atrial dilatation.

Methods A tetracycline-regulated transgene was used to express JDP2 specifically in the mouse heart. Mice hearts were dissected and subjected to Northern and Western analysis, or analyzed by ECG recording and echocardiography. Regulation of gene expression was studied using electromobility shift assays and luciferase gene reporter analysis.

Results Expression of JDP2 resulted in massive bi-atrial dilatation, defects in conduction, and a lethal phenotype. These effects were developmentally independent, acquired during adulthood, and were reversible upon abolishing of JDP2 expression. Connexin 40 and myosin light chain 2a expression were identified as potential target genes.

Conclusion Expression of basic leucine zipper transcription inhibitors is sufficient to results in atrial dilatation. This dilatation is acquired postnatally and is reversible. Thus, basic leucine zipper transcription inhibitors may be a relevant therapeutic target for preventing atrial dilatation and atrial fibrillation.

KEYWORDS Trial function; Hypertrophy; Connexins; Gene expression


Time for primary review 33 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Nucleic Acids ResHome page
K. Weidenfeld-Baranboim, K. Bitton-Worms, and A. Aronheim
TRE-dependent transcription activation by JDP2-CHOP10 association
Nucleic Acids Res., June 1, 2008; 36(11): 3608 - 3619.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.